[go: up one dir, main page]

HK1217670A1 - Albu-bche调配物、其制造方法和用途 - Google Patents

Albu-bche调配物、其制造方法和用途 Download PDF

Info

Publication number
HK1217670A1
HK1217670A1 HK16105646.9A HK16105646A HK1217670A1 HK 1217670 A1 HK1217670 A1 HK 1217670A1 HK 16105646 A HK16105646 A HK 16105646A HK 1217670 A1 HK1217670 A1 HK 1217670A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
present
lyophilized pharmaceutical
provides
aqueous
Prior art date
Application number
HK16105646.9A
Other languages
English (en)
Inventor
Zhao Qinghai
Luo Xia
Bock Jason
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1217670A1 publication Critical patent/HK1217670A1/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Mechanical Engineering (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16105646.9A 2013-01-15 2014-01-14 Albu-bche调配物、其制造方法和用途 HK1217670A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752740P 2013-01-15 2013-01-15
US61/752,740 2013-01-15
PCT/US2014/011401 WO2014113359A1 (en) 2013-01-15 2014-01-14 Formulations of albu-bche, preparation and uses thereof

Publications (1)

Publication Number Publication Date
HK1217670A1 true HK1217670A1 (zh) 2017-01-20

Family

ID=51165300

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105646.9A HK1217670A1 (zh) 2013-01-15 2014-01-14 Albu-bche调配物、其制造方法和用途

Country Status (7)

Country Link
US (1) US9409662B2 (zh)
EP (1) EP2945703A4 (zh)
AR (1) AR094481A1 (zh)
CA (1) CA2896793A1 (zh)
HK (1) HK1217670A1 (zh)
MX (1) MX2015009141A (zh)
WO (1) WO2014113359A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1217670A1 (zh) 2013-01-15 2017-01-20 Teva Pharmaceutical Industries Ltd. Albu-bche调配物、其制造方法和用途
EP3322310B1 (en) * 2015-07-13 2021-09-29 Philip Morris Products S.A. Producing an aerosol-forming composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367090B1 (en) 1988-11-01 1994-01-12 Schwarz Pharma Ag Lyophilized MDM composition and method of making it
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US20040087014A1 (en) 2000-11-28 2004-05-06 Huse William D Eukaryotic expression libraries and methods of use
US20030096401A1 (en) 2000-11-28 2003-05-22 Huse William D. Eukaryotic expression libraries and methods of use
ATE437891T1 (de) 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
US20030153062A1 (en) 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
IL142875A (en) 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
US6989261B2 (en) 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7049121B2 (en) 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1458860A2 (en) 2001-12-21 2004-09-22 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
US20050136044A1 (en) 2003-12-04 2005-06-23 Watkins Jeffry D. Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
US20060039870A1 (en) 2004-08-20 2006-02-23 Turner Jeffrey D Pulmonary delivery of enzymatic medical countermeasures
CA2577017A1 (en) 2004-08-30 2006-03-09 Tercica, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
EP1896610A2 (en) 2005-05-03 2008-03-12 Handylab, Inc. Lyophilized pellets
US7438904B1 (en) 2005-10-04 2008-10-21 University Of Kentucky Research Foundation High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
MX2009000418A (es) * 2006-07-10 2009-08-12 Univ Columbia Composiciones en contra de la cocaina y tratamiento.
NZ594056A (en) * 2009-01-16 2013-03-28 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2782838A1 (en) * 2009-12-08 2011-06-16 Teva Pharmaceutical Industries Ltd. Bche albumin fusions for the treatment of cocaine abuse
US20140030321A1 (en) 2011-04-12 2014-01-30 Endocyte, Inc. Solid pharmaceutical composition
AR093908A1 (es) 2012-12-12 2015-06-24 Teva Pharma Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
MX2015008944A (es) 2013-01-15 2016-06-21 Teva Pharma Proceso de liofilizacion.
HK1217670A1 (zh) 2013-01-15 2017-01-20 Teva Pharmaceutical Industries Ltd. Albu-bche调配物、其制造方法和用途

Also Published As

Publication number Publication date
WO2014113359A1 (en) 2014-07-24
EP2945703A1 (en) 2015-11-25
EP2945703A4 (en) 2016-08-31
MX2015009141A (es) 2016-03-16
US20140199283A1 (en) 2014-07-17
AR094481A1 (es) 2015-08-05
US9409662B2 (en) 2016-08-09
CA2896793A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
MX2012000036A (es) Vacuna.
SG10201809694PA (en) Antibody neutralizing human respiratory syncytial virus
EP4599847A3 (en) Prefusion coronavirus spike proteins and their use
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
MX2021010519A (es) Proteinas f de rsv de prefusion y su uso.
NZ711567A (en) Antibody formulations
PH12013500872A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
MX2024010472A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
SG10201906859PA (en) Novel proteins specific for angiogenesis
EA201170217A1 (ru) Гибридные полипептидные антигены респираторно-синцитиального вируса
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CA2863949A1 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
WO2011112856A3 (en) Novel protein peptide hydrogels
WO2012012388A3 (en) Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途
HK1217670A1 (zh) Albu-bche调配物、其制造方法和用途
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
WO2014115084A3 (en) Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof